• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Icon acquires Aptiv Solutions to strengthen adaptive design capabilities

Icon acquires Aptiv Solutions to strengthen adaptive design capabilities

March 31, 2014
CenterWatch Staff

Seeking to enhance its capabilities in the design and execution of portfolio-wide adaptive clinical trials for pharmaceutical, biotech and medical device companies, Icon has agreed to acquire Aptiv Solutions, a global services company focused on enhancing clinical trial decision-making, for $143.5 million in cash.

In acquiring Aptiv, based in Reston, Va., Icon will enhance its software product support for the design, simulation and analysis of adaptive trials. Aptiv’s software also is used by the FDA and regulators in Europe and Japan.

“Icon is the perfect fit,” said Pat Donnelly, chairman and CEO of Aptiv Solutions. “With the globalization of clinical trials and our existing capabilities, we needed to quickly get into Latin America, parts of Asia and other marketplaces. Our deal with Icon enables us to fulfill our strategy. For them, they get leading adaptive design expertise and decision-making capabilities moving into phase II rather than waiting for pivotal phase III trials.  And there is almost zero client overlap.”

Donnelly said the two companies began acquisition talks last fall about how the two might fit together, but did not discuss the economics of the deal until December. He noted both companies have a shared focus on innovation that will position the combined entity as “the go-to service provider for design and execution of adaptive trials for drug, diagnostic and medical companies in a fast-growing marketplace.”

For Icon, the Aptiv acquisition provides added experience in the management of medical device trials, leveraging its adaptive capabilities and regulatory expertise to expedite the development of a wide range of medical devices. Aptiv’s software, called ADDPLAN,  is used by  more than 50 large pharmaceutical and medical device companies and  academic researchers.

Icon also gains Aptiv’s recently formed consortium of major drug companies collaboratively developing new statistical methodologies for the design of innovative dose-finding clinical trials, with an emphasis on adaptive designs. The co-founding companies are Novartis Pharma, Janssen Pharmaceuticals and Eli Lilly.

Nuala Murphy, president, Icon Clinical Research Services, said Aptiv’s adaptive trial capabilities “will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing